nelmastobart (STT-003) / STCube Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    A phase 1b/2 study of Nelmastobart with Capecitabine in Patients with Refractory mCRC (Poster Hall (Exhibit Halls AB); Virtual) -  Oct 30, 2025 - Abstract #SITC2025SITC_1650;    
    These findings support further evaluation in larger, randomized trials, with an emphasis on biomarker-driven patient selection strategies.Acknowledgements This study was supported by grants and research funds from STCube Pharmaceutical.Trial Registration NCT05990543Ethics Approval This study was approved by the IRB of Korea University Anam Hospital under the designation 2023AN0515.Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    Nelmastobart Combination Shows Excellent Tolerability and Early Antitumor Activity in Refractory mCRC (Poster Hall (Exhibit Halls AB); Virtual) -  Oct 30, 2025 - Abstract #SITC2025SITC_1631;    
    P1, P1/2
    The study was conducted in accordance with the Declaration of Helsinki and with all applicable laws and regulations of the locale and country where the study was conducted, and in compliance with Good Clinical Practice Guidelines. The number of the IRB approval is 2025AN0204.Consent In this study, we don't contain sensitive and identifiable information about patients.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma, Tecentriq (atezolizumab) / Roche
    BTN1A1 Blockade Enhances Chemotherapy-Induced Anti-Tumor Immunity in Preclinical Lung Cancer Models (Poster Hall (Exhibit Halls AB); Virtual) -  Oct 3, 2025 - Abstract #SITC2025SITC_765;    
    In zebrafish xenografts, hSTC810 + Docetaxel produced the greatest tumor regression without inducing observable toxicity or developmental delay.Conclusions Across three physiologically relevant NSCLC models, hSTC810 synergized with Docetaxel to suppress tumor growth by enhancing immune-mediated cytotoxicity. These findings support BTN1A1 as a viable immunotherapeutic target and justify clinical development of hSTC810 in combination with chemotherapy, particularly for patients with PD-L1-refractory or immune-desert NSCLC.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    Enrollment closed, Phase classification, Trial completion date:  hSTC810: Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Sep 9, 2025   
    P1/2,  N=59, Active, not recruiting, 
    These findings support BTN1A1 as a viable immunotherapeutic target and justify clinical development of hSTC810 in combination with chemotherapy, particularly for patients with PD-L1-refractory or immune-desert NSCLC. Not yet recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 | Trial completion date: Mar 2026 --> Dec 2026
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    BTN1A1 and Nuclear YAP1 Co-Expression as Predictive Biomarkers for Nelmastobart Efficacy in Lung Cancer: Findings From a Phase 1 Trial (Exhibit Hall) -  Jul 22, 2025 - Abstract #IASLCWCLC2025IASLC_WCLC_1513;    
    Conclusions : Preliminary results from the TMA analysis and Phase 1 trial suggest that targeting BTN1A1 with Nelmastobart is safe and shows early signs of clinical activity in lung cancer, particularly among patients with high nuclear YAP1 expression. These findings support further investigation in larger, biomarker-enriched clinical trials to validate BTN1A1 and YAP1 as predictive biomarkers and confirm the therapeutic efficacy of Nelmastobart in lung cancer.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    A phase I study of hSTC810 (Nelmastobart), an anti-BTN1A1 antibody, in patients with advanced solid tumors (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 30, 2024 - Abstract #SITC2024SITC_1914;    
    A copy of the letter of approval and the IRB/IEC membership roster were received by the Sponsor prior to any drug shipment. 2 Ethical Conduct of the Study The study was conducted in accordance with the Declaration of Helsinki and with all applicable laws and regulations of the locale and country where the study was conducted, and in compliance with Good Clinical Practice Guidelines.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    Development and efficacy of a bispecific antibody targeting BTN1A1 and PD-L1 in cancer immunotherapy (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_536;    
    Conclusions In vitro and in vivo data show that treatment with bispecific antibodies (hSTC810 and anti-PD-L1) significantly enhances antitumor activity compared to treatment alone. Our findings suggest that this represents a new immune checkpoint capable of overcoming antitumor resistance by targeting a broad spectrum of colon cancers using bispecific antibodies.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    Trial completion, Trial completion date, Monotherapy:  A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) (clinicaltrials.gov) -  Mar 15, 2024   
    P1,  N=47, Completed, 
    Our findings suggest that this represents a new immune checkpoint capable of overcoming antitumor resistance by targeting a broad spectrum of colon cancers using bispecific antibodies. Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Feb 2024
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    BTN1A1-Targeted Immunotherapy Combined with Standard Therapy in Small Cell Lung Cancer (SCLC) and Colorectal Cancer (Exhibit Hall B) -  Sep 27, 2023 - Abstract #SITC2023SITC_921;    
    The organoids were examined for morphologic disruption following hPBMC, hSTC810, and Paclitaxel treatment by assessing the organoid size and formation rate...Conclusions In vitro, in vivo, and clinical data show that hSTC810 treatment results in the activation of innate immune response pathways and enhances anti-tumor activity when combined with anti-PD-L1 therapy. Our results suggest that BTN1A1 is a novel immune checkpoint that can be targeted to overcome resistance to conventional therapies in SCLC patients.
  • ||||||||||  nelmastobart (STT-003) / STCube Pharma
    Enrollment open, Monotherapy:  A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001) (clinicaltrials.gov) -  Apr 25, 2022   
    P1,  N=66, Recruiting, 
    A copy of the written consent is available for review by the Editor of this journal. Not yet recruiting --> Recruiting